Biotech

Arch Biopartners announced the good manufacturing practice production campaign for AB569 has advanced to the GMP glass vial filling stage.

Arch Biopartners (TSXV:ARCH; OTCBB:ACHFF) announced the good manufacturing practice (GMP) production campaign for AB569 has advanced to the GMP glass vial filling stage.
As quoted in the press release:

AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients as well as many other indications.
AB569 is a potential stand alone or complementary treatment to existing and emerging standard of care therapies for CF and COPD patients that have reduced lung function due to multi-drug resistant bacterial infections.

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20206.41+106.60
TSXV700.54+3.89
DOW32223.42+26.76
S&P 5004008.010.00
NASD11662.79-142.21
ASX7093.00+17.90

COMMODITIES

Commodities
Gold1833.08+5.82
Silver21.73+0.12
Copper4.27+0.08
Palladium2087.63+77.63
Platinum963.52+18.52
Oil114.43+0.23
Heating Oil3.75-0.02
Natural Gas8.22+0.26

DOWNLOAD FREE REPORTS

×